Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

CYTORI THERAPEUTICS INC (CYTX)
Mes dernières consult.
Most popular
Report
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 7,63 M
EBIT 2017 -19,3 M
Net income 2017 -22,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 15,8 M
EBIT 2018 -10,1 M
Net income 2018 -14,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 1,20x
Capi. / Sales2018 0,58x
Capitalization 9,13 M
More Financials
Company
Cytori Therapeutics, Inc. is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions.Data from preclinical studies and clinical trials suggest that Cytori Cell... 
More about the company
Surperformance© ratings of Cytori Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CYTORI THERAPEUTICS INC
11/29 CYTORI THERAPEUTICS, INC. (NASDAQ : CYTX) Files An 8-K Material Modification to ..
11/28 CYTORI THERAPEUTICS, INC. : Material Modification to Rights of Security Holders,..
11/28 Cytori Closes Rights Offering for Gross Proceeds of $10 Million
11/25 CYTORI THERAPEUTICS : Announces Expiration of Oversubscribed Rights Offering
11/24 Cytori Announces Expiration of Oversubscribed Rights Offering
11/23 CYTORI THERAPEUTICS : Maxim`s Target Price on Biotech Makes It More Than a Tenba..
11/21 CYTORI THERAPEUTICS : Reports Reduction in Fibrosis Parameters in Scar Study
11/20 Cytori Reports Reduction in Fibrosis Parameters in Scar Study
11/16 Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
11/16 CYTORI THERAPEUTICS : Reminds Stockholders That Rights Offering Expires on Tuesd..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
12:37p ESSILOR INTERNATIONAL : Luxottica CEO exits eyewear giant ahead of Essilor merge..
12/14 EXCLUSIVE : Luxottica, Essilor tie-up on track for unconditional EU okay - sourc..
12/11DJESSILOR INTERNATIONAL : Luxottica Group Will Have New CEO, Says Chief -FT
12/08 Toshiba, Western Digital aiming to settle chip dispute next week - sources
12/08 TOSHIBA, WESTERN DIGITAL AIMING TO S : sources
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
2016 Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2016 Results - Earnings Ca..
2016 Cytori Therapeutics EPS in-line, beats on revenue
2016 Cytori Cell Therapy an Orphan Drug in Europe for scleroderma-related hand dys..
2016 Notable earnings after Tuesday?s close
2016 Cytori's late-stage study of ECCS-50 in scleroderma 50% enrolled; study to co..
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,08 $
Spread / Average Target 701%
EPS Revisions
Managers
NameTitle
Marc H. Hedrick President, Chief Executive Officer & Director
David M. Rickey Chairman
Tiago Girão CFO, Vice President & Head-Investor Relations
John K. Fraser Chief Scientist
Mark T. Marino Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CYTORI THERAPEUTICS INC-4.14%9
MEDTRONIC PLC14.88%113 017
BAXTER INTERNATIONAL45.96%35 594
C R BARD INC47.78%24 382
ZIMMER BIOMET HOLDINGS INC10.00%23 333
HOYA CORPORATION12.50%18 958